Methods for detecting a Mycobacterium tuberculosis infection

Details Methods for detecting a Mycobacterium tuberculosis infection Methods for detecting a Mycobacterium tuberculosis infection

2007-03-14

2011-11-08

Minnifield, Nita M (Department: 1645)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S007100, C435S007200, C435S007320

Reexamination Certificate

active

08053181

ABSTRACT:
Methods for detecting an infection withMycobacterium tuberculosis(Mtb) in a subject are disclosed. The methods include detecting the presence of CD8+T cells that specifically recognize an Mtb polypeptide. The methods include in vitro assays for detecting the presence of CD8+T cells in a biological sample, and in vivo assays that detect a delayed type hypersensitivity reaction. The methods can also include detecting Mtb polypeptides and polynucleotides. Reagents for the detection of an Mtb infection are also disclosed.

REFERENCES:
patent: 6294328 (2001-09-01), Fleischmann et al.
patent: 6384018 (2002-05-01), Content et al.
patent: 6555653 (2003-04-01), Alderson et al.
patent: 7074559 (2006-07-01), Kapur et al.
patent: 7332340 (2008-02-01), Tyagi et al.
patent: 7364869 (2008-04-01), Nixon et al.
patent: 7424370 (2008-09-01), Sachdeva et al.
patent: 7510718 (2009-03-01), Krohn et al.
patent: 7767209 (2010-08-01), Staib et al.
patent: 7842299 (2010-11-01), Lewinsohn et al.
patent: 7867704 (2011-01-01), Kapur et al.
patent: 2002/0098200 (2002-07-01), Campos-Neto et al.
patent: 2002/0176867 (2002-11-01), Anderson et al.
patent: 2002/0192229 (2002-12-01), Flyer et al.
patent: 2003/0147897 (2003-08-01), Anderson et al.
patent: 2003/0175725 (2003-09-01), Kapur et al.
patent: 2004/0029129 (2004-02-01), Wang et al.
patent: 2004/0057963 (2004-03-01), Anderson et al.
patent: 2004/0141985 (2004-07-01), Lalvani et al.
patent: 2005/0074822 (2005-04-01), Nixon et al.
patent: 2005/0123511 (2005-06-01), McCreavy et al.
patent: 2005/0288866 (2005-12-01), Sachdeva et al.
patent: 2007/0026020 (2007-02-01), Ernst et al.
patent: 2007/0036816 (2007-02-01), Campos-Neto et al.
patent: 2007/0042383 (2007-02-01), Kapur et al.
patent: 2008/0124549 (2008-05-01), Lee et al.
patent: 2009/0070897 (2009-03-01), Goldman et al.
patent: 2009/0124549 (2009-05-01), Lewinsohn et al.
patent: 2009/0324503 (2009-12-01), Lewinsohn et al.
patent: 2010/0129391 (2010-05-01), Reed et al.
patent: 2011/0014224 (2011-01-01), Lewinsohn et al.
patent: 1 484 405 (2004-12-01), None
patent: 2207035 (2010-07-01), None
patent: WO 98/53075 (1998-11-01), None
patent: WO 99/24577 (1999-05-01), None
patent: WO 01/51639 (2001-07-01), None
patent: WO 01/62893 (2001-08-01), None
patent: WO 01/74130 (2001-10-01), None
patent: WO 01/79257 (2001-10-01), None
patent: WO 03/033530 (2003-04-01), None
patent: WO 2005/076010 (2005-08-01), None
patent: WO 2005/090988 (2005-09-01), None
patent: WO 2007/106536 (2007-09-01), None
patent: WO 2007/106560 (2007-09-01), None
patent: WO 2009/039854 (2009-04-01), None
patent: WO 2010/034007 (2010-03-01), None
patent: WO 2010/034007 (2010-03-01), None
Garnier et al, PNAS, USA, 2003, 100:7877-7882.
Li et al, PNAS, USA, 2005, 102:12344-12349.
Seki et al, Vaccine, 2009, 27:1710-1716.
Stinear et al, Genome Research, 2008, 18:729-741.
Stinear et al, Genome Research, 2007, 17:192-200.
Braibant et al, FEMS Microbiol. Rev., 2000, 24/4:449-467.
Cole et al, Nature, 1998, 393:537-544.
Brosch et al, PNAS, USA, 2007, 104:5596-5601.
Berzofsky et al, J. Clin. Invest., 2004, 113:1515-1525.
Restifo et al, Gene Therapy, 2000, 7:89-92.
Gura, Science, 1997, 278:1041-1042.
Steinman et al, Science, 2004, 305:197-200.
Winthrop et al, Clin. J. Am. Soc. Nephrol., 2008, 3:1357-1363.
Khan et al, Clinical and Vaccine Immunology, Mar. 2008, 15/3:433-438.
Nyendak et al, Curr. Opin. Infect. Dis., 2009, 22:174-182.
Lewinsohn et al, J. Immunol, 2000, 165:925-930.
Lewinsohn et al, Curr. Opin. Pediatr., 2010, 22:71-76.
Lewinsohn, Pediatric Infectious Disease Journal, Aug. 2009, 28/8:674-675.
Cho, Yonsei Medical Journal, 2007, 48/3:347-359.
Mazurek et al, MMWR, Recommendations and Reports, Dec. 16, 2005, 54(RR15):49-55.
Pai et al, Lancet Infect Diseases, 2004, 4:761-776.
Wang et al, Immunology, 2011, 132:482-491.
Hokey et al, Tuberculosis, 2011, 91:82-85.
Abebe e t al, Clinical and Developmental Immunology, 2011, vol. 2011, 11 pages.
Ahmad, Clinical and Developmental Immunology, 2011, vol. 2011, 17 pages.
Fleishmann et al., “Whole-Genome Comparison ofMycobacterium tuberculosisClinical and Laboratory Strains,”Journal of Bacteriology, 184(19):5479-5490, (Oct. 2002).
Fleishmann et al., Whole genome comparison ofMycobacterium tuberculosisclinical and laboratory strains, Entry C137—MYCTU,EMBL, (2002).
Grotzke and Lewinsohn, “Role of CD8+ T lymphocytes in control ofMycobacterium tuberculosisinfection,”Microbes and Infection, 7(4):776-788, (Apr. 4, 2005).
International Search report for PCT Application No. PCT/US2007/006534; 6 pp., (Oct. 2, 2007).
International Search report for PCT Application No. PCT/US2007/006472; 7 pp., (Nov. 23, 2007).
Lewinsohn, David et al., “Characterization of Human CD8+T Cells Reactive withMycobacterium tuberculosis-infected Antigen-presenting Cells,”Journal of Experimental Medicine, 187(10):1633-1640, (May 18, 1998).
Lewinsohn, Deborah et al., “Human Dendritic Cells Presenting Adenovirally Expressed Antigen ElicitMycobacterium tuberculosis-Specific CD8+ T Cells,” American Journal of Respiratory and Critical Care Medicine, 166(6):843-848, (Sep. 15, 2002).
Smith et al., “Human CD8+CTL Specific for the Mycobacterial Major Secreted Antigen 85A,”Journal of Immunology, 165:7088-7095, (2000).
Arend et al., “Antigentic Equivalence of Human T-Cell Responses toMycobacterium Tuberculosis-Specific RD1-Encoded Protein Antigens ESAT-6 and Culture Filtrate Protein 10 and to Mixtures of Synthetic Peptides,”Infection and Immunity68(6):3314-3321 (Jun. 2000).
Bixler et al.,Synthetic Vaccines1:39-71 (1987).
Blythe et al., “An Analysis of the Epitope Knowlesge Related to Mycobacteria,”Immunome Research3(10) 14 pages (2007).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Science Amino Acid Substitutions,”Science247:1306-1310 (1990).
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,”Journal of Cell Biology111:2129-2138 (1990).
Camus et al., “Re-annotation of the Genome Sequence ofMycocaterium tuberculosisH37Rv,”Microbiology148:2967-2973 (2002).
Creighton,Protein Structure: A Practical Approach, pp. 184-186 (1989).
Creighton,Proteins: Structures and Molecular Properties, pp. 314-315 (1984).
Database Accession No. P0A4W4, “Uncharacterized ABC Transporter ATP-Binding Protein Rv1273c/MT1311,” 3pp. (Mar. 2005).
Delogu and Fadda, “The Quest for a New Vaccine Against Tuberculosis,”Journal Infection in Developing Countries3(1):5-15 (2009) (Abstract only).
Doherty et al., “Tuberculosis Subunit Vaccines: From Basic Science to Clinical Testing,”Expert Opin. Biol. Ther. 7(10):1539-1549 (2007).
Ellner, “The Emergence of Extensively Drug-Resistant Tuberculosis: A Global Health Crisis Requiring New Interventions: Part II: Scientific Advances that May Provide Solutions,”CTS2(1):80-84 (2008).
Greenspan and Di Cera, “Defining Epitopes: It's Not as Easy as it Seems,”Nature Biotechnology, 17:936-937 (Oct. 1999).
Grotzke et al., “Role of CD8+ T lymphocytes in Control ofMycobacterium TuberculosisInfection,”Microbes and Infection7:776-788 (2005).
Gupta et al., “Current Status of TB Vaccines,”Vaccine25:3742-3751 (2007).
Houghten et al., “Relative Importance of Position and Individual Amino Acid Residues in Peptide Antigen-Antiboy Interactions: Implications in the Mechanism of Antigenic Drift and Antigenic Shift,”Vaccines86:21-25 (1986).
Kawamura, “Protective Immunity AgainstMycobacterium tuberculosis,” Kekkaku81(11):6887-691 (Nov. 2006) (Abstract only).
Kumar et al., “Amino Acid Variations at a Single Residue in an Autoimmune Peptide Profoundly Affect its Properties: T-Cell Activation, Major Histocompatibility Complex Binding, and Ability to Block Experimental Allergic Encephalomyelitis

Affiliated with

Also associated with

Rating

Methods for detecting a Mycobacterium tuberculosis infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for detecting a Mycobacterium tuberculosis infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for detecting a Mycobacterium tuberculosis infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4258859